Capital Research Global Investors Kymera Therapeutics, Inc. Transaction History
Capital Research Global Investors
- $479 Billion
- Q2 2025
A detailed history of Capital Research Global Investors transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 1,262,182 shares of KYMR stock, worth $50.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,262,182
Previous 365,190
245.62%
Holding current value
$50.3 Million
Previous $10 Million
451.09%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding KYMR
# of Institutions
217Shares Held
72.2MCall Options Held
178KPut Options Held
64.6K-
Price T Rowe Associates Inc Baltimore, MD6.86MShares$273 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6.65MShares$265 Million2.94% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.56MShares$261 Million5.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.62MShares$224 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.5MShares$219 Million9.44% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.18B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...